| scholarly article | Q13442814 |
| P50 | author | Vassilios Vassiliou | Q57419282 |
| Haralampos Moutsopoulos | Q87896552 | ||
| John Ioannidis | Q6251482 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 741-747 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome | |
| P478 | volume | 46 |
| Q41652024 | A BAFF receptor His159Tyr mutation in Sjögren's syndrome-related lymphoproliferation |
| Q50090015 | Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome |
| Q37776830 | Activation of the type I interferon pathway in primary Sjogren’s syndrome |
| Q43545216 | Active immunological profile is associated with systemic Sjögren's syndrome |
| Q54216578 | Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road? |
| Q38120318 | Are the B cells cast with the leading part in the Sjogren's syndrome scenario? |
| Q36436250 | Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. |
| Q37448413 | Autoimmunity and hematologic malignancies: associations and mechanisms |
| Q36392366 | B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue |
| Q36956210 | B-cell lymphoproliferation in chronic inflammatory rheumatic diseases |
| Q26796484 | B-cell survival factors in autoimmune rheumatic disorders |
| Q90415036 | Bronchus-associated lymphoid tissue lymphoma (BALT) in a patient with primary Sjögren's syndrome |
| Q89888459 | Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome |
| Q87115714 | Characterization and Comparison of Patient Subgroups Suspicious for IgG4-Related Disease and Malignant Lymphoma in Patients Followed-up for Sjögren's Syndrome |
| Q47106367 | Clinical Profile and Significance of Mucocutaneous Lesions of Primary Sjögren's Syndrome: A Large Cross-sectional Study with 874 Patients |
| Q38133017 | Clinical aspects of autoimmune rheumatic diseases |
| Q33745659 | Clinical course, prognosis, and cause of death in primary Sjögren's syndrome |
| Q46512541 | Clinical features distinguishing lymphoma development in primary Sjögren's syndrome—A retrospective cohort study |
| Q34712157 | Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients |
| Q43432949 | Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome |
| Q45169996 | Complement and autoimmunity |
| Q38055866 | Connective Tissue Disease–Associated Lung Disease |
| Q35555698 | Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome |
| Q86601056 | Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome? |
| Q53879622 | Critical overview of outcome parameters for patients with primary Sjögren's syndrome |
| Q40785165 | Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients |
| Q40076686 | Current and prospective treatment options for Sjögren's syndrome |
| Q38021493 | Current treatment of hepatitis C-associated rheumatic diseases |
| Q50892871 | Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients |
| Q37835368 | Dermatologic Manifestations of Sjögren Syndrome |
| Q38178271 | Diagnostic Approaches to Sjögren's syndrome: a Literature Review and Own Clinical Experience |
| Q26766486 | Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases |
| Q80629257 | End-stage renal failure in adolescence with Sjögren's syndrome autoantibodies SSA and SSB |
| Q56657612 | Epidemiologie des primären Sjögren-Syndroms |
| Q34473582 | Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003. |
| Q35236341 | Establishment of a novel diagnostic model for Sjögren's syndrome by proteomic fingerprinting |
| Q36135689 | Extranodal Marginal Zone Lymphoma of the Lung: Evolution from an Underlying Reactive Lymphoproliferative Disorder |
| Q57753875 | Extrasalivary lymphoma development in Sjögren's syndrome: Clonal evolution from parotid gland lymphoproliferation and role of local triggering |
| Q36943071 | Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors |
| Q84601421 | Frequency of systemic manifestations in patients with primary Sjögren's syndrome in Argentina |
| Q36161211 | Gene therapeutics in Sjögren's syndrome |
| Q36971042 | HCV-related autoimmune and neoplastic disorders: the HCV syndrome |
| Q48459103 | Haralampos M. Moutsopoulos: A lifetime in autoimmunity |
| Q35237312 | Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer |
| Q38217806 | Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis |
| Q33235736 | Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis |
| Q35148626 | Immunopathogenesis of Sjögren's syndrome |
| Q64936636 | Immunophenotypes and clinical features of lymphocytes in the labial gland of primary Sjogren's syndrome patients. |
| Q34513422 | Impaired clearance of early apoptotic cells mediated by inhibitory IgG antibodies in patients with primary Sjögren's syndrome |
| Q43444343 | Incidence of cancer in a cohort of patients with primary Sjogren's syndrome |
| Q36715254 | Interaction between comorbidity and cancer |
| Q88991504 | Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome |
| Q79448779 | Is interstitial pneumonia in patients with collagen diseases a contraindication to lung cancer surgery? |
| Q37284531 | Is the blood B-cell subset profile diagnostic for Sjogren syndrome? |
| Q41790742 | Large scale evidence and replication: insights from rheumatology and beyond |
| Q84711351 | Latest update on the primary Sjögren's syndrome |
| Q35637439 | Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). |
| Q47676033 | Lymphocytic alveolitis: A surprising index of poor prognosis in patients with primary Sjogren's syndrome |
| Q35082778 | Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome |
| Q41888927 | Lymphoma and other malignancies in primary Sjögren's syndrome |
| Q35637298 | Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors |
| Q35756957 | Lymphoproliferative disorders in Sjögren's syndrome |
| Q33652396 | MALT Lymphoma of Minor Salivary Glands in a Sjögren's Syndrome Patient: a Case Report and Review of Literature |
| Q41259985 | MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome |
| Q41586037 | Magnetic resonance sialography of the parotid glands in chronic hepatitis C virus patients with and without vasculitis |
| Q44716572 | Malignancy and autoimmunity: causally or casually related? |
| Q38029322 | Malignancy as a comorbidity in rheumatic diseases |
| Q38118422 | Malignant lymphoma in primary Sjögren’s syndrome: An update on the pathogenesis and treatment |
| Q36942539 | Mixed cryoglobulinemia |
| Q39556608 | Mixed cryoglobulinemia-associated Sjögren's syndrome leading to spontaneous rupture of the kidney: a case report |
| Q47784216 | Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study |
| Q40230222 | Natural history and Predictors of Progression to Sjögren's Syndrome Among Participants of the SICCA registry. |
| Q54935864 | Neurological manifestations of primary Sjögren's syndrome. |
| Q40238844 | New approaches in Sjögren's syndrome therapy |
| Q81440372 | Non HCV-related mixed cryoglobulinemia |
| Q90012060 | Parotid abscess secondary to brucellosis in a patient with primary Sjögren's syndrome |
| Q37777643 | Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome |
| Q61447149 | Personality, depression and anxiety in primary Sjogren's syndrome - Association with sociodemographic factors and comorbidity |
| Q36998409 | Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome. |
| Q41472929 | Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. |
| Q38180823 | Predicting progression to lymphoma in Sjögren's syndrome patients |
| Q35130185 | Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients |
| Q37205067 | Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. |
| Q38032377 | Predictors for the development of non-Hodgkin lymphoma in primary Sjögren's syndrome |
| Q36407549 | Primary Gougerot-Sjögren syndrome: a dermatological approach |
| Q37352805 | Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality |
| Q36152109 | Primary Sjögren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients |
| Q35171162 | Primary Sjögren syndrome in childhood: report of a case and review of the literature |
| Q84780249 | Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia |
| Q36677386 | Primary Sjögren's syndrome as a systemic disease: A study of participants enrolled in an International Sjögren's syndrome registry |
| Q51470499 | Primary Sjögren's syndrome with minimal change disease—A case report |
| Q38905170 | Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers |
| Q35555323 | Primary Sjögren's syndrome: new clinical and therapeutic concepts |
| Q83455031 | Primary and Secondary Sjogren-Jones Syndromes—Historical Evolution |
| Q55055463 | Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome |
| Q47710355 | Prognostic value of cryoglobulins, protein electrophoresis, and serum immunoglobulins for lymphoma development in patients with Sjögren's syndrome. A retrospective cohort study. |
| Q36391445 | Progress and regression within primary Sjögren's syndrome |
| Q37745058 | Rapidly Developed Multiple Face and Neck Skin Cancers in a Patient with Sjögren's Syndrome: A Case Report. |
| Q26786130 | Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies |
| Q38526786 | Renal involvement in primary Sjögren's syndrome |
| Q55174868 | Risk factors for primary Sjögren syndrome-associated interstitial lung disease. |
| Q26753072 | Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis |
| Q46223982 | Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome |
| Q90415297 | Role of miR200b-5p miRNA in lymphomagenesis associated with Sjögren's syndrome (SS) |
| Q89669149 | Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome |
| Q34743817 | Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort |
| Q55970263 | Sjogren's syndrome |
| Q51626446 | Sjogren’s syndrome: An update on clinical, basic and diagnostic therapeutic aspects |
| Q90415366 | Sjögren Syndrome Associated with Inflammatory Muscle Diseases |
| Q34975201 | Sjögren Syndrome-Associated Small Fiber Neuropathy: Characterization From a Prospective Series of 40 Cases |
| Q38260354 | Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management |
| Q87353703 | Sjögren syndrome |
| Q40385292 | Sjögren syndrome or sjögren disease? The histological and immunological bias caused by the 2002 criteria |
| Q43429635 | Sjögren's syndrome and non-Hodgkin's lymphoma: from pathophysiology to treatment |
| Q36951063 | Sjögren's syndrome--a plethora of clinical and immunological phenotypes with a complex genetic background |
| Q36997269 | Sjögren's syndrome--study of autoantigens and autoantibodies |
| Q37053804 | Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly |
| Q34261915 | Sjögren’s syndrome, the old and the new |
| Q90296272 | Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study |
| Q48249597 | Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients |
| Q45461798 | Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases |
| Q60948114 | TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients |
| Q45348203 | The co-occurrence of Hashimoto thyroiditis in primary Sjogren's syndrome defines a subset of patients with milder clinical phenotype |
| Q36056942 | Treating Sjögren’s syndrome: insights for the clinician |
| Q51015200 | Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren’s Syndrome: A Retrospective Clinical Study |
| Q37912214 | Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? |
| Q38180717 | Type I IFN signature in primary Sjögren's syndrome patients |
| Q36042432 | Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis |
| Q34130258 | United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease |
| Q38559605 | Update on Pathogenesis of Sjögren's syndrome |
| Q35552189 | Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome |
| Q52911750 | Vasculopathy in Sjögren's syndrome |
| Q36329266 | Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management |
| Q79145258 | [Sjögren's syndrome. Current aspects from a rheumatological point of view] |
Search more.